{
    "clinical_study": {
        "@rank": "65542", 
        "acronym": "AVANT", 
        "arm_group": [
            {
                "arm_group_label": "niacin", 
                "arm_group_type": "Experimental", 
                "description": "niacin titrated up to 6 grams taken orally every day for 12 weeks"
            }, 
            {
                "arm_group_label": "sugar pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "taken orally every day for 12 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is looking to see if niacin will lessen atherosclerotic plaque inflammation and\n      favorably affect circulating levels of endothelial progenitor cells and microparticles in\n      people with atherosclerotic disease on chronic statin therapy."
        }, 
        "brief_title": "Assessment Of Vascular Health After Niacin Therapy (AVANT)", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Coronary Artery Disease", 
            "Carotid Artery Disease", 
            "Lower Extremity Peripheral Artery Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carotid Artery Diseases", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Peripheral Arterial Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men age 55 years and above with coronary artery disease or women age 65 years and\n             above with coronary artery disease OR Men age 45 years and above with both coronary\n             artery disease and carotid or lower extremity peripheral artery disease or women age\n             55 years and above with both coronary artery disease and carotid or lower extremity\n             peripheral artery disease.\n\n          -  Subjects must be on statin monotherapy, defined as a stable statin dose for at least\n             12 weeks, with no anticipated need for further titration during the study period\n\n        Exclusion Criteria:\n\n          -  Anxiety or claustrophobia prohibiting imaging\n\n          -  History of allergy to intravenous contrast, iodine, or shellfish\n\n          -  Renal insufficiency\n\n          -  History of allergy or severe intolerance to niacin\n\n          -  History of diabetes mellitus or elevated fasting glucose\n\n          -  Moderate to severe gout\n\n          -  Peptic ulcer disease\n\n          -  Acute coronary syndrome, transient ischemic attack or cerebrovascular accident, or\n             acute limb ischemia in the preceding 12 months\n\n          -  Heart failure or unstable angina pectoris\n\n          -  Use of daily non-statin lipid-altering therapy prior to the initiation of study\n             medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003638", 
            "org_study_id": "812962"
        }, 
        "intervention": [
            {
                "arm_group_label": "niacin", 
                "intervention_name": "Niacin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "sugar pill", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Niacin", 
                "Nicotinic Acids", 
                "Niacinamide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "University of Pennsylvania"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 12-WEEK STUDY EVALUATING THE EFFECTS OF NIACIN ON VASCULAR HEALTH ASSESSED BY Fluorodeoxyglucose-PET/CT AND CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND MICROPARTICLES", 
        "overall_official": {
            "affiliation": "University of Pennsylvania", 
            "last_name": "Emil deGoma, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline in arterial Fluorodeoxyglucose (FDG) uptake assessed by FDG-PET/CT", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change from baseline in circulating endothelial progenitor cells", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change from baseline in endothelial-derived microparticles", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change from baseline in platelet-derived microparticles", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change from baseline in monocyte-derived microparticles", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003638"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pennsylvania", 
            "investigator_full_name": "Emil deGoma", 
            "investigator_title": "Assistant Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}